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We propose a new biomathematical method, OncoFinder, for both quantitative and
qualitative analysis of the intracellular signaling pathway activation (SPA). This method
is universal and may be used for the analysis of any physiological, stress, malignancy
and other perturbed conditions at the molecular level. In contrast to the other existing
techniques for aggregation and generalization of the gene expression data for individual
samples, we suggest to distinguish the positive/activator and negative/repressor role of
every gene product in each pathway. We show that the relative importance of each
gene product in a pathway can be assessed using kinetic models for "low-level" protein
interactions. Although the importance factors for the pathway members cannot be so far
established for most of the signaling pathways due to the lack of the required experimental
data, we showed that ignoring these factors can be sometimes acceptable and that the
simplified formula for SPA evaluation may be applied for many cases. We hope that due
to its universal applicability, the method OncoFinder will be widely used by the researcher
community.
Keywords: mitogenic signaling pathways, microchip transcriptome investigation, targeted anti-cancer drugs,
expression level profiling, signalome profiling, stochastic robustness analysis
Intracellular signaling pathways (SPs) regulate numerous pro-
cesses involved in normal and pathological conditions including
development, growth, aging, and cancer. Many bioinformatic
tools have been developed recently that analyze SPs. However,
none of them makes it possible to efficiently do the high-
throughput quantification of pathway activation scores for the
individual biological samples. Here we propose a method for
quick, informative and large-scale screening of changes in signal-
ing pathway activation (SPA) in cells and tissues. These changes
may reflect various differential conditions like differences in phys-
iological state, aging, disease, treatment with drugs, infections,
media composition, additives, etc. One of the potential applica-
tions of SPA studies may be in utilizing mathematical algorithms
to identify and rank the medicines based on their predicted
efficacy.
The information about SPA can be obtained from the mas-
sive proteomic or transcriptomic data. Although the proteomic
level may be somewhat closer to the biological function of SPA,
the transcriptomic level of studies today is far more feasible in
terms of performing experimental tests and analyzing the data.
The transcriptomic methods like Next-generation sequencing
(NGS) or microarray analysis of RNA can routinely determine
expression levels for all or virtually all human genes (Shirane
et al., 2004). Transcriptome profiling may be performed for the
minute amount of the tissue sample, not necessarily fresh, but
also for the clinical formalin-fixed, paraffin-embedded (FFPE)
tissue blocks. For the molecular analysis of cancer, gene expres-
sion can be interpreted in terms of abnormal SPA features of
various pro- and antimitotic SPs. Such analysis may improve fur-
ther decision-making process of treatment strategy selection by
the clinician.
Pro- and antimitotic SPs that determine various stages of
cell cycle progression remained in the spotlight of the computa-
tional biologists for more than a decade (Kholodenko et al., 1999;
Borisov et al., 2009; Kuzmina and Borisov, 2011). Today, hun-
dreds of SPs and related gene product interaction maps that show
sophisticated relationships between the individual molecules,
are cataloged in various databases like UniProt (The UniProt
consortium, 2011), HPRD (Mathivanan et al., 2006), QIAGEN
SABiosciences (SABiosciences), WikiPathways (Bauer-Mehren
et al., 2009), Ariadne Pathway Studio (Nikitin et al., 2003),
SPIKE (Elkon et al., 2008), Reactome (Haw and Stein, 2012),
KEGG (Nakaya et al., 2013), etc. One group of bioinformatic
approaches integrated the analysis of transcriptome-wide data
with the models employing the mass action law and Michaelis-
Meten kinetics (Yizhak et al., 2013). These methods which were
developing during last 15 years, however, remained purely fun-
damental until recently, primarily, because of the multiplicity of
interaction domains in the signal transducer proteins that enor-
mously increase the interactome complexity (Conzelmann et al.,
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2006; Borisov et al., 2008). Secondly, a considerable number of
unknown free parameters, such as kinetics constants and/or con-
centrations of protein molecules, significantly complicated the
SPA analysis. Yizhak et al. (2013) suggested that the clinical effi-
ciency of several drugs, e.g., geroprotectors, may be evaluated as
the ability to induce the kinetic models of the pathways into the
steady state. However, protein-protein interactions were quan-
titatively characterized in detail only for a tiny fraction of SPs.
This approach is also time-consuming since to process each tran-
scriptomic dataset it requires extensive calculations for the kinetic
models (Yizhak et al., 2013).
However, all the contemporary bioinformatical methods that
were proposed for digesting large-scale gene expression data fol-
lowed by recognition and analysis of SPs, have an important
disadvantage. They do not allow tracing the overall pathway acti-
vation signatures and quantitively estimate the extent of SPA
(Kuzmina and Borisov, 2011; Hwang, 2012; Yizhak et al., 2013).
This may be due to lack of the definition of the specific roles of
the individual gene products in the overall signal transduction
process, incorporated in the calculation matrix used to estimate
SPA.
Here we propose a new method that, to our knowledge, for
the first time makes it possible to quantitatively estimate SPA
for individual samples basing on the large-scale gene expression
data. The method was previously announced by our team here
(Zhavoronkov et al., 2014). Theoretically, the signal transduction
efficiency at every stage of the SP depends on the concentrations
of the interacting gene products. The computational modeling
of the signal transduction processes indicated that most of the
interacting proteins can be found in the living cells at the con-
centrations significantly lower than the saturation levels for each
transduction step (Birtwistle et al., 2007; Borisov et al., 2009). Our
model is based on the correlation of the signal transducer concen-
trations and the overall SPA. We also determined the overall indi-
vidual roles of certain gene products in the functioning of each
individual SP. These roles can be either positive or negative signal
transduction regulators; alternatively, for some proteins the roles
may be undefined or neutral. Finally, these roles may be charac-
terized quantitatively depending on the individual importances
of the individual interactors in the overall SPA. The determina-
tion of these roles for each individual SP is a non-trivial task
that has several uncertainties. Namely, protein interactions within
each pathway may be competitive or independent, and there-
fore, belong to a sequential or parallel series of the nearby events
(Borisov et al., 2006; Conzelmann et al., 2006). The overall graph
for the protein interaction events may include both sequential
(pathway-like) and parallel (network-like) edges (Conzelmann
et al., 2006; Borisov et al., 2008). The role of each gene product
in the signal transduction may depend on whether it works in a
sequential or a parallel way. Alternatively, as the raw approxima-
tion of this situation, one may propose a simplified method that
utilizes only the overall roles of each gene product in the SPA.
In this case, each simplified signaling graph includes only two
types of branches of protein interaction chain: one for sequen-
tial events that promote SPA, and another for repressor sequential
events. Under these conditions, it can be presumed that all activa-
tor/repressor members have equal importances for the SPA, and
come to the following formula for the overall signal outcome (SO)
of a given pathway, SO =
∏N
i= 1[AGEL]i∏M
j= 1[RGEL]j
. Here the multiplication is
done over all possible activator and repressor proteins in the path-
way, [AGEL]i and [RGEL]j are relative gene expression levels of
activator (i) and repressor (j) members, respectively. To obtain
an additive value, it is possible to take the logarithmic levels of
gene expression, and thus come to a function of pathway activa-
tion strength, PAS, which operates with the experimental datasets
obtained during comprehensive profiling of gene expression, for a
pathway p, PASp =∑n ARRnp · lg(CNRn). Here the case-to-norm
ratio, CNRn, is the ratio of the expression levels of a gene n in
the sample (e.g., of a cancer patient) and in the control (e.g.,
average value for healthy group). The discrete value ARR (acti-
vator/repressor role) shows whether the gene product promotes
SPA (1), inhibits it (−1) or plays an intermediate role (0.5, 0
or −0.5, respectively). Negative and positive overall PAS values
correspond, respectively, to decreased or increased activity of SP
in a sample, with the extent of this activity proportional to the
absolute value of PAS.
However, the assumption of sequential protein-protein inter-
action in pathways may seem rather artificial. Although it is
difficult to precisely estimate the importance of certain gene
products that act in the pathway in a non-sequential mode, the
solution may come from the kinetic models of SPA that use
the “low-level” approach of mass action law describing each act
of protein interactions. Some of these models were previously
experimentally validated by us and others using Western blot
analysis (Kholodenko et al., 1999; Kiyatkin et al., 2006; Birtwistle
et al., 2007; Borisov et al., 2009; Kuzmina and Borisov, 2011).
Our previous experience suggests that the two approaches can
be used to estimate the importance of distinct genes/proteins in
the pathways. One of them operates with the concept of sen-
sitivity of the ordinary differential equation system with the
free parameters (Kholodenko et al., 2003), which is generally
applied to kinetic constants, but may be used for assperating
with the protein concentrations in the kinetic model of a path-
way (Kuzmina and Borisov, 2011), according to a formula,w(1)j =
1
T
∫ T
0
∣∣
∣ ∂ ln[EFF(t)]∂ lnjC tot
∣∣
∣ dt. Here w is the importance factor, [EFF(t)] is
the time-dependent concentration of the active pathway effector
protein (experimentally traced marker of a pathway activation),
the upper integration limit T is the time of reaching the steady-
state, and Ctotj is the total concentration for the protein j.
Another way to calculate the importance factor for the gene
products deals with the stiffness/sloppiness analysis of the effector
activation (Daniels et al., 2008). This approach comprises analyz-
ing the Hesse matrix, Hij = ∂2∂C toti ∂C totj
∑
k
(
[EFF(C tot ,tk)]−[EFF]expk
)2
σ2k
,
whereCtot is the vector of total concentrations for every protein in
the pathway, [EFF(Ctot, tk)] is concentration of an active pathway
effector protein at the time point tk, [EFF]expk is the experimen-
tally measured (e.g., by Western blots) total concentration of
the effector at the same time, and σk is the experimental error
for this measurement. The sloppiness/stiffness analysis looks for
the eigenvalues, λm, and eigenvectors, ξm, for the Hesse matrix,
Hξm = λm · ξm. The higher is the absolute value of λn, the
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“stiffer” is the direction within the n-dimensional space of Ctot
(where n is the number of protein types in the pathway model).
The eigenvector components along with the stiffest direction, ξs,
may be used for assessment of the importance factorw of a certain
gene products in a pathway according to the formula:w(2)j =
∣
∣ξsj
∣
∣.
Taking into account the above considerations, we come to
the following final formula for assessing the SPA: PAS(1, 2)p =∑
n ARRnp · BTIFn · w(1,2)n · lg(CNRn). Here the Boolean flag
BTIF (beyond tolerance interval flag) indicates that the expres-
sion level for the gene n for the given sample is different enough
from the respective expression level in the reference sample or
set of reference samples. For this demonstration of our method
we applied two simultaneous restriction/inclusion criteria to the
expression of each individual gene: (i) 50% expression level cut-
off rate compared to the average for the reference set, and (ii) the
sample expression level should differ stronger than two standard
deviations from the average of the reference set.
We next explored the effect of the introduction of the impor-
tance factors w in calculating PAS compared to the simplified
model of PAS evaluation lacking w. Importance factors were
calculated using either sensitivity-based, w(1), or stiffness-based,
w(2), algorithms. We performed this verification for the EGFR
pathway, for which we established and published this model pre-
viously (Kuzmina and Borisov, 2011). For these two sets of the
importance factors, and for the w-free model, we performed a
computational analysis of nine transcriptomes established using
microarray hybridization technology for human glioblastoma
samples from the published datasets (Supplementary dataset 1).
The information on SP organization was taken from the Web-
based SABiosciences database. The data on ARR were manually
curated by analyzing the same database. Our findings suggest that
the cloud of values for the ratio
PAS(1)EGFR
PASEGFR
(where PASEGFR is the
PAS value for the EGFR pathway in the simplified model, where
all importance factors equal to 1) lies within the interval of (0.6
± 0.8), whereas the ratio PAS
(2)
EGFR
PASEGFR
belonged to the interval (1.0 ±
0.8). Overall, we conclude that for such a complex SP like EGFR
which includes >300 gene products, incorporation of the impor-
tance factors had only a moderate effect on the PAS. This suggests
that, in principle, the simplified formula for PAS calculation may
be applied for the pathway analysis.
For the overwhelming majority of the SPs, there is no experi-
mental data available that makes impossible for them to calculate
the importance factors using kinetic models. For them we per-
formed the stochastic robustness analysis using the simplified
formula for PAS. We introduced the additional random pertur-
bation factor, wn, which was used as the analog of importance
factor for PAS evaluation. In our computational simulation, the
distribution of wn was logarithmically normal and calculated
as follows: wn = 2xn , where xn were normally distributed ran-
dom numbers with the expected value of M = 0 and standard
deviation σ = 0.5. The random perturbation factors wn were
applied to the glioblastoma transcriptional dataset GSM215422
(GSM215422 dataset). Importantly, although the perturbation
was done independently 98 times with independent weighting
factors wn, for each gene, the values of standard deviation for
FIGURE 1 | Values of pathway activation strength (APAS) that were
calculated using the 98 random trials, each having random
log-normally distributed weighting factors wn, vs. non-perturbed PAS
for the different SPs, calculated using OncoFinder method. The
pathway information was extracted from the SABiosciences database.
Primary data are shown on the Supplementary dataset 3. For the perturbed
values (APAS), both average values (points at the plot) and standard
deviation bars are shown.
the set of alternate PAS (APAS) were nor big enough to mask
the proportional trend between the average perturbed PAS and
unperturbed PAS for each of the 68 SPs analyzed in this study
(Figure 1; Supplementary dataset 2).
We propose here a new biomathematical method, OncoFinder,
for both quantitative and qualitative analysis of the intracellular
SP activation. It can be used for the analysis of any physiological,
stress, malignancy and other perturbed conditions at the molecu-
lar level. The enclosedmathematical algorithm enables processing
of high-throughput transcriptomic data, but there is no tech-
nical limitation to apply OncoFinder to the proteomic datasets
as well, when the developments in proteomics allow generating
proteome-wide expression datasets. We hope that due to its uni-
versal applicability, the method OncoFinder will be widely used
by the biomedical researcher community and by all those inter-
ested in thorough characterization of the molecular events in the
living cells. We also want to encourage building international
scientific partnership aimed at the standardized experimental
characterization of the importance factors for individual proteins,
starting at least with the SPs most relevant to the major aspects of
human physiology.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be
found online at: http://www.frontiersin.org/journal/10.338
9/fgene.2014.00055/abstract
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